Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/199544
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Klimek, Ludger | - |
dc.contributor.author | Brehler, Randolf | - |
dc.contributor.author | Mösges, Ralph | - |
dc.contributor.author | Demoly, Pascal | - |
dc.contributor.author | Mullol i Miret, Joaquim | - |
dc.contributor.author | Wang, De Yun | - |
dc.contributor.author | O'Hehir, Robyn | - |
dc.contributor.author | Didier, Alain | - |
dc.contributor.author | Kopp, Matthias Volkmar | - |
dc.contributor.author | Bos, Catherine | - |
dc.contributor.author | Karagiannis, Efstratios | - |
dc.date.accessioned | 2023-06-21T09:19:38Z | - |
dc.date.available | 2023-06-21T09:19:38Z | - |
dc.date.issued | 2022-06-15 | - |
dc.identifier.issn | 2164-554X | - |
dc.identifier.uri | http://hdl.handle.net/2445/199544 | - |
dc.description.abstract | Sublingual immunotherapy (SLIT) is a well-tolerated, safe, and effective approach to treating allergic rhinitis (AR). Oralair (R) is a five-grass pollen SLIT tablet containing natural pollen allergens from five of the major grass species responsible for seasonal AR due to grass pollen allergy. Recommended use is in a pre-coseasonal regimen, starting daily treatment approximately 4 months before the start of the pollen season, with treatment then continued daily throughout the season; treatment should continue for 3-5 y. Clinical efficacy and safety of Oralair (R) in patients with grass pollen-induced AR has been demonstrated in a comprehensive clinical development program of randomized controlled trials. Effectiveness has been substantiated in subsequent observational studies with sustained efficacy following treatment cessation and a favorable level of adherence, quality of life, benefit, and satisfaction for the patients. Supportive evidence for a benefit in reducing the risk or delaying the development of allergic asthma is emerging. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Taylor and Francis | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1080/21645515.2022.2066424 | - |
dc.relation.ispartof | Human Vaccines & Immunotherapeutics, 2022, vol. 18, num. 5 | - |
dc.relation.uri | https://doi.org/10.1080/21645515.2022.2066424 | - |
dc.rights | cc by-nc-nd (c) Klimek, Ludger et al, 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) | - |
dc.subject.classification | Rinitis | - |
dc.subject.classification | Gramínies | - |
dc.subject.classification | Antihistamínics | - |
dc.subject.other | Rhinitis | - |
dc.subject.other | Grasses | - |
dc.subject.other | Antihistamines | - |
dc.title | Update about Oralair® as a treatment for grass pollen allergic rhinitis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-06-20T10:49:52Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 9315900 | - |
dc.identifier.pmid | 35704772 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Update_about_Oralair.pdf | 730.62 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License